Clinical Implications of Resistance to Direct-Acting Antivirals
Thursday May 19, 2016
Stockton University | 11 am–4 pm
Galloway, NJ 08205
Free Conference | 2.5 CME’s
Chronic liver disease, including the disease resulting from Hepatitis C viral infection and NASH, comprises the 12th leading cause of death in the United States across all population groups, with total deaths of 36,427 (11.5/100,000 population) annually. Recent advances and refinements in the treatment of HCV and NASH are the subjects of this important conference. The 4th Annual Hepatitis C Conference will address current research and clinical developments in the diagnosis and treatment of HCV/ NASH with an overall goal of increasing the knowledge and competence of physicians and allied medical personnel in providing optimal care for patients with these conditions.
- Upon completion of “Clinical Implications of Resistance to Direct-Acting Antivirals”, participants should be able to discuss the basic principles of drug resistance, to describe relevant resistance profiles for each class of direct-acting antiviral agents (DAAs), and to select appropriate management approaches to avoid virologic failure resulting from pre-existing or emergent associated variants (RAVs).
- Upon completion of “New Management in the Treatment of Hepatitis C”, participants should be able to understand new therapies approved during the past year for the management of Hepatitis C virus and to describe the new therapies, contraindications, efficacy, and advocacy.
- Upon completion of “New Concepts in the Treatment of NASH”, participants should be able to define NASH (nonalcoholic steatohepatitis) and describe its symptomology and to enumerate current treatments for NASH, including behavioral recommendations and emerging liver-directed pharmacotherapy.
This activity is designed for physicians in the practice of hepatology, gastroenterology, and surgery as well as allied medical personnel, including nurses, physician assistants, and nurse practitioners involved in the diagnosis and management of chronic liver disease, including Hepatitis C and NASH.
Method of Participation
To meet the learning objectives and receive continuing education credits, participants are expected to check in at the registration desk, attend the program in person, and complete an online evaluation form at the conclusion of the activity. A letter certifying attendance and credit verification will be emailed to participants upon completion of the online evaluation survey.
Stockton University is located off the Garden State Parkway on Jimmie Leeds Road, Galloway, NJ 08205. Park in Lot 3. The conference will be held in Building F, Room 101. Driving Direction to Stockton University.
The University of Nebraska Medical Center accredits this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim credits that are commensurate with the extent of their participation in the activity.
Education Director and Presenter
John Santoro, DO, FACG, FACOI, FAGA, ASGE
Medical Director of Atlantic Gastroenterology Associates Hepatitis Treatment Center, Dr. Santoro currently serves as Governor of the board of directors for the state of New Jersey for the American College of Gastroenterology, and was named “2014 Physician of the Year” by the Crohn’s & Colitis Foundation of America Philadelphia/Delaware Chapter. He is a frequent lecturer and author of many articles on Hepatitis C.
Kenneth D. Rothstein, MD, FACG, ABIM
Dr Rothstein is a leading hepatology expert, is Associate Professor of Medicine, and Chief of the Division of Gastroenterology and Hepatology, Drexel University College of Medicine. He also serves as medical director of Abdominal Transplantation at Hahnemann University Hospital.
Paul J. Thuluvath, MD, MBBS, FACG, AGAF, FRCP
Dr. Thuluvath is Chief, Division of Gastroenterology at Mercy Medical Center, and Medical Director for the Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy, a frequent lecturer and published author of journal articles, leads a top-rated physician team of gastroenterology specialists in Baltimore, Maryland, who help patients find the best treatment options for digestive diseases and liver conditions.
11:00 – 11:30 Registration
11:30 – 12:30 Lunch
12:30 – 1:30 Clinical Implications of Resistance to Direct-Acting Antivirals
- Paul Thuluvath, MD,
- Chief, Division of Gastroenterology at The Institute for Digestive Health & Liver Disease and Medical Director for the Melissa L. Posner Institute for Digestive Health and Liver Disease at Mercy Medical Center, Baltimore, MD.
1:30 – 2:15 New Concepts in the Treatment of NASH
- Kenneth Rothstein, MD
- Chief of the Division of Gastroenterology and Hepatology at Drexel University College of Medicine and Medical Director of Abdominal Transplantation at Hahnemann University Hospital, Philadelphia, PA
2:15 – 2:30 Break
2:30 – 3:15 New Management in the Treatment of Hepatitis C
- John Santoro, DO
- Director of Atlantic Gastro Hepatitis Treatment Center, Egg Harbor Township, NJ
3:15 – 4:00 Q&A